Efficacy of risperidone in children with disruptive behavioural disorders

Duhig, Michael J., Saha, Sukanta and Scott, James G. (2013) Efficacy of risperidone in children with disruptive behavioural disorders. Journal of Paediatrics and Child Health, 49 1: 19-26. doi:10.1111/j.1440-1754.2011.02200.x


Author Duhig, Michael J.
Saha, Sukanta
Scott, James G.
Title Efficacy of risperidone in children with disruptive behavioural disorders
Journal name Journal of Paediatrics and Child Health   Check publisher's open access policy
ISSN 1034-4810
Publication date 2013-01
Year available 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/j.1440-1754.2011.02200.x
Volume 49
Issue 1
Start page 19
End page 26
Total pages 8
Place of publication Oxford, England, U.K.
Publisher Wiley-Blackwell Publishing
Collection year 2012
Language eng
Abstract This study aims to review the evidence for the efficacy of risperidone in the treatment of disruptive behavioural disorders (DBDs) in children and adolescents. Established databases were searched using the terms 'Risperidone and efficacy and children' and 'Risperidone and efficacy and adolescents'. Randomised, double-blind controlled studies were retained for analysis. Janseen-Cilag was contacted to identify any unpublished studies. Quality of studies was measured using Jadad scores. Seven studies of 657 subjects with a mean age of 9.9years (SD= 2.0) (range 4-18years) were identified. Only one study was judged to use the highest quality of methodology according to the Jadad score. Patients with DBD who were treated with risperidone showed clinical improvement compared with placebo. Weight gain, somnolence and gastrointestinal complaints were common. Risperidone was found to be efficacious in reducing symptoms in children and adolescents with DBD. However, studies were mostly of short duration and had deficiencies in the descriptions of blinding and randomisation. Research using rigorous methodology examining the long-term outcomes of efficacy and safety are required to inform clinicians and families of the therapeutic benefits and risks of risperidone in this clinical population.
Keyword Adolescents
Children
Disruptive behavioural disorders
Efficacy
Risperidone
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article in Press. Article first published online: 3 November 2011

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2012 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 15 Nov 2011, 08:01:43 EST by James Scott on behalf of Psychiatry - Royal Brisbane and Women's Hospital